Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in March 2018 on request of the Sponsor.
On 26 March 2014, orphan designation (EU/3/14/1254) was granted by the European Commission to Alexion Europe SAS, France, for eculizumab for the prevention of graft rejection following solid organ transplantation.
Prevention of graft rejection following solid organ transplantation
|Orphan designation status||
|EU designation number||
|Date of designation||
Alexion Europe S.A.S.
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: